Psilocybin for Mental Health: Conditions With Clinical Evidence

Psilocybin has been clinically studied for depression, anxiety, PTSD, addiction, alcoholism, and end-of-life distress. Below is an overview of the evidence by condition and links to detailed guides.

Conditions With Clinical Evidence

Evidence Overview

Audience Guides

Frequently Asked Questions

What conditions does psilocybin treat?

Psilocybin has been clinically studied for treatment-resistant depression, major depressive disorder, anxiety, PTSD, alcohol use disorder, and end-of-life existential distress. The FDA has granted Breakthrough Therapy designation for treatment-resistant depression and major depressive disorder. As of 2026, psilocybin is not FDA-approved for any condition but is legal for supervised use in Oregon, Colorado, and New Mexico.

Is psilocybin approved for any mental health condition?

Psilocybin is not FDA-approved for any mental health condition as of 2026. It holds FDA Breakthrough Therapy designation for treatment-resistant depression (2018) and major depressive disorder (2019), meaning the FDA recognises promising early clinical evidence and has fast-tracked development. FDA approval is anticipated between 2026 and 2028 pending Phase 3 trial completion.

Which condition has the strongest evidence for psilocybin?

Depression and end-of-life anxiety have the strongest clinical evidence. A 2021 NEJM randomised controlled trial found two doses of psilocybin non-inferior to six weeks of escitalopram (an SSRI) for treatment-resistant depression. Multiple Johns Hopkins and NYU trials have shown large, rapid reductions in end-of-life anxiety and depression. PTSD, addiction, and alcoholism have strong emerging evidence from Phase 2 trials.

Can psilocybin help with addiction?

Yes — psilocybin has demonstrated promising results for alcohol use disorder and tobacco cessation in clinical trials. A 2022 JAMA Psychiatry trial found that two sessions of psilocybin-assisted therapy produced significantly greater reductions in alcohol consumption than placebo. A Johns Hopkins pilot study reported 67% tobacco abstinence at 12 months after psilocybin treatment, compared to 35% for standard cessation therapies.

How does psilocybin compare to standard treatments for depression?

A 2021 NEJM randomised controlled trial directly compared two doses of psilocybin against six weeks of daily escitalopram (a standard SSRI antidepressant). Psilocybin was non-inferior on the primary outcome and showed numerically better remission rates (28.9% vs 14.4%) and significantly better secondary outcomes including emotional well-being and psychological connectedness.

Is psilocybin therapy legal for mental health treatment in the US?

Psilocybin remains a Schedule I controlled substance federally. Supervised psilocybin therapy is legal for adults in Oregon (licensed programs since June 2023), Colorado (licensed programs since June 2025), and via New Mexico's Medical Psilocybin Act (targeting full launch late 2026). Outside these state programs, psilocybin therapy is not legally accessible in the US.

Related

For the full therapeutic protocol, how to find a facilitator, and what to expect in a session, see our therapy guide. For legal retreat options, see our retreats directory.